We will attend ESMO Congress 2026, where the international oncology community will examine new clinical evidence and developments influencing cancer research, treatment and patient care.
Our oncology team brings together clinical development, regulatory, feasibility and operational perspectives. We can help sponsors consider how emerging evidence may affect study strategy, identify practical risks early and prepare for delivery across European countries and sites. Meet us in Madrid to discuss your oncology trial and the decisions ahead.
Meet the Clarenta team
- > Diana Gheorghi , Director, Business Development
- > Biljana Stuparevic , Director, Business Development
- > Céline Leparquier , Clinical and Regulatory Affairs Director
- > Philippe Drevot, Clinical Development Director
Our team will be available to discuss early phase oncology development, scientific and regulatory planning, patient and site feasibility, and the operational considerations that may affect study timelines and delivery across Europe.
If you are attending ESMO Congress 2026, arrange a meeting with us to discuss your oncology development plans and the questions that should be addressed early.
